- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06448754
Volrustomig 프라이밍 요법 탐색적 2상 플랫폼 연구 (eVOLVE-01)
고형 종양 환자를 대상으로 다른 항암제와 병용한 Volrustomig 프라이밍 요법의 안전성, 내약성, 약동학, 면역원성 및 항종양 활성을 평가하기 위한 제2상 공개 라벨 연구(eVOLVE-01)
Purpose of this study is to assess the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of volrustomig in combination with other anticancer drugs in participants with specified solid tumors.
연구 개요
상태
정황
상세 설명
This Phase II, platform, open-label, multicenter study will evaluate the efficacy, safety, and tolerability of volrustomig in combination with anticancer drugs in various solid tumor types.
This platform study currently includes 2 substudies:
Substudy 1: metastatic non-small cell lung cancer (mNSCLC) (non-squamous [NSQ]). Participants will be randomized in two treatment arms: Arm 1A and Arm 1B.
Substudy 2: mNSCLC (squamous [SQ] or NSQ). Participants will enroll to the Arm 2A only.
All arms will test a volrustomig dosing in combination with chemotherapy.
연구 유형
등록 (실제)
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
-
Batumi, 그루지야, 6010
- Research Site
-
Tbilisi, 그루지야, 0144
- Research Site
-
Tbilisi, 그루지야, 0112
- Research Site
-
Tbilisi, 그루지야, '0159
- Research Site
-
Tbilisi, 그루지야, 186
- Research Site
-
Tbilisi, 그루지야, 0114
- Research Site
-
-
-
-
-
Athens, 그리스, 115 27
- Research Site
-
Athens, 그리스, 12462
- Research Site
-
Elaiones, 그리스, 546 23
- Research Site
-
Piraeus, 그리스, 185 47
- Research Site
-
Thessaloniki, 그리스, 57001
- Research Site
-
-
-
-
-
Changhua, 대만, 50006
- Research Site
-
New Taipei City, 대만, 23561
- Research Site
-
Taipei, 대만, 106
- Research Site
-
Taipei, 대만, 110
- Research Site
-
-
-
-
-
Seongnam, 대한민국, 13620
- Research Site
-
Seoul, 대한민국, 03722
- Research Site
-
Suwon, 대한민국, 16247
- Research Site
-
-
-
-
-
Cluj-Napoca, 루마니아, 400641
- Research Site
-
Craiova, 루마니아, 200542
- Research Site
-
Floreşti, 루마니아, 407280
- Research Site
-
-
-
-
-
Kuala Lumpur, 말레이시아, 59100
- Research Site
-
Kuching, 말레이시아, 93586
- Research Site
-
Perai, 말레이시아, 13700
- Research Site
-
-
-
-
California
-
Los Angeles, California, 미국, 90067
- Research Site
-
-
North Carolina
-
Chapel Hill, North Carolina, 미국, 27514
- Research Site
-
-
-
-
-
Belgrade, 세르비아, 11000
- Research Site
-
-
-
-
-
Geneva, 스위스, 1205
- Research Site
-
Lausanne, 스위스, 1011
- Research Site
-
Winterthur, 스위스, 8401
- Research Site
-
Zurich, 스위스, 8091
- Research Site
-
-
-
-
-
A Coruña, 스페인, 15009
- Research Site
-
Alcorcón, 스페인, 28922
- Research Site
-
Barcelona, 스페인, 08041
- Research Site
-
Madrid, 스페인, 28041
- Research Site
-
Málaga, 스페인, 29004
- Research Site
-
Pamplona, 스페인, 31008
- Research Site
-
Santander, 스페인, 39008
- Research Site
-
Santiago de Compostela, 스페인, 15706
- Research Site
-
Valencia, 스페인, 46026
- Research Site
-
Valencia, 스페인, 46015
- Research Site
-
-
-
-
-
Genoa, 이탈리아, 16132
- Research Site
-
Meldola, 이탈리아, 47014
- Research Site
-
Milan, 이탈리아, 20133
- Research Site
-
Naples, 이탈리아, 80131
- Research Site
-
Orbassano, 이탈리아, 10043
- Research Site
-
Perugia, 이탈리아, 06132
- Research Site
-
Rozzano, 이탈리아, 20089
- Research Site
-
Udine, 이탈리아, 33100
- Research Site
-
Verona, 이탈리아, 37134
- Research Site
-
-
-
-
-
Beijing, 중국, 100730
- Research Site
-
Hangzhou, 중국, 310014
- Research Site
-
Jinan, 중국, 250013
- Research Site
-
Yantai, 중국, 264000
- Research Site
-
Zhengzhou, 중국, 450000
- Research Site
-
-
-
-
-
Lisbon, 포르투갈, 1649-035
- Research Site
-
Lisbon, 포르투갈, 1169-050
- Research Site
-
Lisbon, 포르투갈, 1400-038
- Research Site
-
Porto, 포르투갈, 4099-001
- Research Site
-
-
-
-
-
Bois-Guillaume, 프랑스, 76031
- Research Site
-
Caen, 프랑스, 14076
- Research Site
-
Dijon, 프랑스, 21079
- Research Site
-
Montpellier, 프랑스, 34070
- Research Site
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Key Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 with no deterioration.
- Life expectancy greater than or equal to (>=) 12 weeks.
- Adequate organ and bone marrow function.
- Body weight greater than (>) 35 kilograms (kg) at screening and at randomization.
- Histologically or cytologically documented NSQ NSCLC in substudy 1 and SQ or NSQ mNSCLC in substudy 2.
- Absence of sensitizing epidermal growth factor receptor (EGFR) mutations.
- Absence of documented tumor genomic alteration results from tests conducted as part of standard local practice in any other actionable driver oncogenes for which there are locally approved targeted 1L therapies.
- At least one measurable lesion not previously irradiated that can be accurately measured at baseline as >= 10 millimeter (mm) in the longest diameter.
Key Exclusion Criteria:
- Spinal cord compression.
- History of primary active immunodeficiency.
- Active or prior documented autoimmune or inflammatory disorders.
- Mixed small-cell lung cancer and NSCLC histology or sarcomatoid variant.
- Brain metastases unless asymptomatic, stable, and not requiring steroids for at least 14 days prior to start of study intervention. A minimum of 2 weeks must have elapsed between the end of radiation therapy and study enrollment.
- Prior chemotherapy or any other systemic therapy for Stage IV NSCLC. Participants who have received prior platinum-containing adjuvant, neoadjuvant, or definitive chemoradiation for local disease are eligible, provided that progression has occurred greater (>) 12 months from end of last therapy.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Substudy 1: Arm 1A: Volrustomig dose regimen 1 + Carboplatin and Pemetrexed
Volrustomig priming dose followed by volrustomig dosing regimen 1 in combination with carboplatin and pemetrexed. |
Participants will receive volrustomig via intravenous (IV) infusion.
다른 이름들:
Participants will receive carboplatin via IV infusion. Participants will receive pemetrexed via IV infusion. |
|
실험적: Substudy 1: Arm 1B: Volrustomig dose regimen 2 + Carboplatin and Pemetrexed
Volrustomig priming dose followed by volrustomig dosing regimen 2 in combination with carboplatin and pemetrexed. |
Participants will receive volrustomig via intravenous (IV) infusion.
다른 이름들:
Participants will receive carboplatin via IV infusion. Participants will receive pemetrexed via IV infusion. |
|
실험적: Substudy 2: Arm 2A: Volrustomig dose regimen 2 +Ramucirumab + Carboplatin + Pemetrexed or Paclitaxel
Volrustomig priming dose followed by volrustomig dosing regimen 2 in combination with ramucirumab and histology-specific chemotherapy (carboplatin+ either pemetrexed or paclitaxel). |
Participants will receive volrustomig via intravenous (IV) infusion.
다른 이름들:
Participants will receive carboplatin via IV infusion. Participants will receive pemetrexed via IV infusion. Participants will receive ramucirumab via IV infusion. Participants will receive paclitaxel via IV infusion. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
기간: From screening (Days -28 to Day -1) up to 2 year 10 months
|
The safety and tolerability of volrustomig in combination with other anticancer drugs in participants with specified solid tumors will be assessed. |
From screening (Days -28 to Day -1) up to 2 year 10 months
|
|
Confirmed Objective Response rate (ORR)
기간: Up to 2 year 10 months
|
ORR is defined as the percentage of participants who have a confirmed complete response (CR) or confirmed partial response (PR), as per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1). |
Up to 2 year 10 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Disease Control Rate (DCR)
기간: Up to 2 year 10 months
|
DCR is defined as the percentage of participants who have a CR or PR or who have stable disease (SD) after the date of randomization or first dose. |
Up to 2 year 10 months
|
|
Duration of Response (DOR)
기간: Up to 2 year 10 months
|
DOR is defined as the time from the date of first documented response until the date of documented progression or death due to any cause (in the absence of progression). |
Up to 2 year 10 months
|
|
Progression Free Survival (PFS)
기간: Up to 2 year 10 months
|
PFS is defined as the time from randomization or first dose until radiological progression or death due to any cause (in the absence of progression). |
Up to 2 year 10 months
|
|
Overall Survival (OS)
기간: Up to 2 year 10 months
|
OS is defined as the time from randomization or first dose until the date of death due to any cause. |
Up to 2 year 10 months
|
|
Serum Concentration of Volrustomig
기간: Up to 2 year 10 months
|
The serum concentrations volrustomig alone and when used in combination with other anticancer agents in participants with pre-specified solid tumors will be assessed. |
Up to 2 year 10 months
|
|
Trough concentration (Ctrough)
기간: Up to 2 year 10 months
|
The trough concentrations volrustomig alone and when used in combination with other anticancer agents in participants with pre-specified solid tumors will be assessed. |
Up to 2 year 10 months
|
|
Maximum Observed Concentration (Cmax)
기간: Up to 2 year 10 months
|
The serum concentrations volrustomig alone and when used in combination with other anticancer agents in participants with pre-specified solid tumors will be assessed. |
Up to 2 year 10 months
|
|
Area Under the Curve (AUC)
기간: Up to 2 year 10 months
|
The AUC concentrations of volrustomig alone and when used in combination with other anticancer agents in participants with pre-specified solid tumors will be assessed. |
Up to 2 year 10 months
|
|
Number of Participants with Positive Antidrug Antibodies (ADAs)
기간: Up to 2 year 10 months
|
The incidence of ADAs against volrustomig or other anticancer agents in serum will be assessed. |
Up to 2 year 10 months
|
공동 작업자 및 조사자
스폰서
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
- 부위별 신생물
- 신생물
- 호흡기 질환
- 폐 질환
- 호흡기 신생물
- 흉부 신생물
- 폐 신생물
- 기관지 암종
- 기관지 신생물
- 암종, 비소세포폐
- 아미노산, 펩티드 및 단백질
- 단백질
- 유기 화학 물질
- 이종 사이 클릭 화합물
- 이종 사이 클릭 화합물, 2- 링
- 이종 사이 클릭 화합물, 융합 링
- 탄화수소
- 사이클로 파라핀
- 탄화수소, alicyclic
- 탄화수소, 순환
- 테르펜
- 항체, 모노클로 날, 인간화
- 항체, 모노클로 날
- 항체
- 면역 글로불린
- 면역 단백질
- 혈액 단백질
- 혈청 글로불린
- 글로불린
- 조정 복합체
- 구아닌
- Hypoxanthines
- 푸리 논
- 퓨린
- 글루타메이트
- 아미노산, 산성
- 아미노산
- 아미노산, 디카 르 복실
- 박습니다
- 사이클로 데카네
- Diterpenes
- 페메트렉시드
- 라무시루맙
- 카르보플라틴
- 파클리탁셀
기타 연구 ID 번호
- D798KC00001
- 2023-509482-20-00 (레지스트리 식별자: CTIS)
- 2023 (미국 NIH 보조금/계약)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Qualified researchers can request access to anonymized individual patient-leveldata from AstraZeneca group of companies sponsored clinical trials via therequest portal Vivli.org. All requests will be evaluated as per the AZ disclosurecommitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure."Yes",indicates that AZ are accepting requests for IPD, but this does not mean allrequests will be approved.
IPD 공유 기간
AstraZeneca will meet or exceed data availability as per the commitment smade to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment athttps://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD 공유 액세스 기준
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure researchenvironmentVivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .